Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Average Rating of "Hold" from Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have been given a consensus rating of "Hold" by the fourteen ratings firms that are covering the firm, MarketBeat reports. Eleven research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $344.82.

Several research analysts have recently commented on MEDP shares. Mizuho reduced their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. William Blair reaffirmed a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Barclays assumed coverage on Medpace in a research note on Tuesday, June 24th. They set an "equal weight" rating and a $300.00 price target on the stock. Leerink Partners assumed coverage on Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Finally, Robert W. Baird dropped their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd.

Insider Transactions at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company's stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director owned 2,998 shares of the company's stock, valued at $904,856.36. This represents a 36.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 20.30% of the company's stock.

Institutional Investors Weigh In On Medpace

Several institutional investors and hedge funds have recently added to or reduced their stakes in MEDP. Geneos Wealth Management Inc. grew its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after buying an additional 37 shares in the last quarter. Brooklyn Investment Group boosted its position in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of Medpace during the fourth quarter valued at $31,000. Whittier Trust Co. boosted its holdings in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after acquiring an additional 35 shares during the period. Finally, Jones Financial Companies Lllp boosted its position in Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after acquiring an additional 110 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Trading Down 1.4%

Shares of MEDP stock traded down $4.53 on Friday, reaching $321.50. 175,561 shares of the company's stock were exchanged, compared to its average volume of 374,914. Medpace has a 52 week low of $250.05 and a 52 week high of $459.77. The stock has a market capitalization of $9.24 billion, a PE ratio of 24.54, a P/E/G ratio of 5.80 and a beta of 1.47. The company's fifty day simple moving average is $303.74 and its 200 day simple moving average is $319.27.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 54.36% and a net margin of 19.31%. The firm had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. During the same period last year, the company earned $3.20 EPS. As a group, sell-side analysts predict that Medpace will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.